Pre-made Gomiliximab biosimilar ( Whole mAb, anti-FCER2 therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-250
Anti-FCER2 therapeutic antibody (Pre-made Gomiliximab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Lumiliximab is an IgG1k monoclonal antibody that targets CD23. It acts as an immunomodulator and was awarded orphan drug status and fast track designation by the FDA.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-FCER2 therapeutic antibody (Pre-made Gomiliximab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||None|
|99% SI Structure||3fzu:HL:CD|
|95-98% SI Structure||None|
|Conditions Discontinued||Allergic asthma;Allergic rhinitis;Chronic lymphocytic leukaemia|